Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H1 2017’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)

– The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects

– The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Aquinox Pharmaceuticals Inc

Astellas Pharma Inc

BELLUS Health Inc

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

Merck & Co Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interstitial Cystitis (Painful Bladder Syndrome) - Overview

Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development

Allergan Plc

Aquinox Pharmaceuticals Inc

Astellas Pharma Inc

BELLUS Health Inc

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

Merck & Co Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA

Interstitial Cystitis (Painful Bladder Syndrome) - Drug Profiles

(heparin + lidocaine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AF-219 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQX-1125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-16357 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mesalamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URG-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects

Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products

Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones

Featured News & Press Releases

Oct 03, 2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer

Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome

May 25, 2016: Aquinox Announces Executive Appointments

May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results

May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego

Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA

Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration

Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference

Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis

Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS

Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC

Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC

Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis

May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms

Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by Allergan Plc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by Aquinox Pharmaceuticals Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by Astellas Pharma Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by BELLUS Health Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by Kytogenics Pharmaceuticals Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by Lipella Pharmaceuticals Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by Merck & Co Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by UCB SA, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by Urigen Pharmaceuticals Inc, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline by Xigen SA, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Dormant Projects, H1 2017

Interstitial Cystitis (Painful Bladder Syndrome) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports